TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Microba Life Sciences Limited ( (AU:MAP) ) has issued an update.
Microba Life Sciences Limited has announced a board renewal process, appointing Mr. Stéphane Chatonsky as an Independent Non-Executive Director to enhance its global commercialization strategy and accelerate the growth of its microbiome testing business. This appointment, effective November 20, 2025, follows the retirement of Non-Executive Directors Mr. Richard Bund and Dr. Hyungtae Kim, who have significantly contributed to the company’s governance and strategic evolution. The board changes aim to strengthen Microba’s position in the industry as it continues to expand its operations globally.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences is a leader in microbiome diagnostics and therapeutics, focusing on improving human health through advanced technology for measuring the human gut microbiome. The company is involved in discovering and developing novel therapeutics for chronic diseases and provides gut microbiome testing services globally to researchers, clinicians, and consumers. Microba collaborates with leading organizations to explore new relationships between the microbiome, health, and disease.
Average Trading Volume: 755,184
Technical Sentiment Signal: Sell
Current Market Cap: A$42.63M
For detailed information about MAP stock, go to TipRanks’ Stock Analysis page.